The tumor embolization devices market consists of sales of tumor embolization devices and related services by entities (organizations, sole traders and partnerships) that manufacture tumor embolization devices. Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. Only goods and services traded between entities or sold to end consumers are included.
The global tumor embolization devices market is expected to decline from $1.45 billion in 2019 to $1.36 billion in 2020 at a compound annual growth rate (CAGR) of -6.24%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.82 billion in 2023 at a CAGR of 10.22%.
